|
Summary:
Gloucester Pharmaceuticals develops and commercializes innovative products for the treatment of cancer. Gloucester’s lead drug, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, was approved in November 2009 by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkins T-cell lymphoma. ISTODAX was officially launched in April 2010. The Company continues to conduct clinical trials in other related cancers, including a registration trial in peripheral T-cell lymphoma (PTCL), to expand upon its approved label indication in CTCL.
Gloucester Pharmaceuticals Case Study
|
